Table 5.
Pre-treatment prediction of biochemical recurrence at 2–10 years in men treated with radiotherapy
| Reference | Year | Prediction form | Biochemical recurrence, years | No of Patients | Variables | Discrimination | Validation |
|---|---|---|---|---|---|---|---|
| External beam radiotherapy | |||||||
| Duchesne et al. [172] | 1996 | Risk group | 5 | 85 | PSA, biopsy Gleason sum | Not available | Not performed |
| Pisansky et al. [173] | 1997 | Risk group | 5 | 500 | Biopsy Gleason sum, clinical stage, PSA | Not available | Internal |
| Zagars et al. [174] | 1997 | Probability graph | 6 | 938 | PSA, biopsy Gleason sum, clinical stage | Not available | Not performed |
| D’Amico et al. [15] | 1999 | Probability table | 2 | 762 | Biopsy Gleason sum, clinical stage, PSA | Not available | Not performed |
| Shipley et al. [175] | 1999 | Probability table | 5 | 1607 | Biopsy Gleason sum, clinical stage, PSA | Not available | Not performed |
| Kattan et al. [81] | 2000 | Probability nomogram development | 5 | 1042 and 1030 | PSA, biopsy Gleason sum, clinical stage, neoadjuvant androgen deprivation therapy, radiation dose delivered | 73% | Internal |
| D’Amico et al. [82, 83] | 1998, 2002 | Probability graph | 5 | 766 | Biopsy Gleason sum, clinical stage, PSA, treatment modality | Not available | Internal |
| Brachytherapy | |||||||
| D’Amico et al. [83] | 1998 | Probability graph | 5 | 218 | Biopsy Gleason sum, clinical stage, PSA, neo-adjuvant therapy | Not available | Not performed |
| Ragde et al. [176] | 1998 | Risk group | 10 | 98 | Age, biopsy Gleason sum, clinical stage, PSA, 45 Gy external beam radiotherapy | 76% | Internal |
| Kattan et al. [84] | 2001 | Probability nomogram development | 5 | 920 and 1827 and 765 | Biopsy Gleason sum, clinical stage, PSA, co-administration of external beam radiotherapy | 61–64% | Internal and external |